SiSaf Ltd’s Post

Missed SLAS earlier this month? Make sure to download our poster! From the 3rd to 7th February, we were in Boston for the Society for Laboratory Automation and Screening (SLAS) International Conference, discussing our work with human iPSC technology for research and drug discovery. Alongside discussions on quality iPSC manufacturing, functional QC and in vitro models, we presented a poster titled "Differentiation of multiple iPSC lines to different cell types to enable cohort analysis in neurodegeneration: challenges and learnings". Listen to our Project Manager, Sian Humphreys presenting the key findings in the poster: https://hubs.la/Q02m2bc70 Click here to download the poster: https://hubs.la/Q02m24Zy0 #iPSCs #SLAS #biotech #StemCells #DrugDiscovery

Lactocore Group is thrilled to announce our fourth patent application, centered on the LCGA-17 peptide's modifications and back-up compounds. Originally, this peptide, which demonstrated anxiolytic activity effects in animal models, had stability concerns within the body. Our goal was to optimize its drug-like properties. Teaming up with Dr. Muttenhaler and harnessing our computational tool, Reptide, we pinpointed chemical alterations to boost plasma stability. Our lead molecule, LCGA-17m16, emerged as a standout in rodent trials, maintaining its target and efficacy. As we advance its preclinical studies, backup compounds are on deck, widening our patent's protective scope. Reptide has revolutionized our approach. It meticulously crafts peptides, enhancing them step by step, and drastically speeds up our data analysis. This paves the path for cutting-edge molecule development. In short, our latest patent application marks a pivotal stride forward, and we're eager to delve into our research's next chapter! #LactocoreResearch #Innovation #AIinPharma #DrugDevelopment #Patent #AI #LactocoreGroup #ImpactInvesting #Longevity #BiotechStartUp #Biotech

🎯 Our Science at NUVISAN: Targeted Protein Degradation (TPD) Traditional drug discovery often revolves around inhibiting protein activity. Here at NUVISAN, we harness cellular machinery to drive protein degradation, advancing drug discovery! Our services include target-finding, degrader design, and synthesis. Explore the capabilities of our integrated TPD platform, leveraging advanced biophysical and biochemical techniques to identify and optimize leads. Additionally, our high-throughput cell-based assays swiftly identify cell-permeable compounds for protein degradation. 📧 Explore PROTAC and Molecular Glue technology with our captivating infographics: https://lnkd.in/djs8YDrY #OurScience #ProteinDegradation #PROTACTechnology #DrugDiscovery #InnovativeScience #TPD #MolecularGlue #theScienceCRO

🧬 At Sibylla, we're thrilled to unveil a turning point for the biotech sector! Our groundbreaking cotranslational protein folding simulation platform is live. 👩🔬 Thanks to our proprietary computational platform, we can predict the folding pathways of proteins while they are synthesized by the ribosome. This means we can characterize long-lived metastable states appearing during the folding process and hosting druggable pockets hidden in the native state. 🚀 Implications? Huge. 💊 This enables us to explore the folding intermediate states as a new class of therapeutic targets. Our disrupting PPI-FIT (Pharmacological Protein Inactivation by Folding Intermediate Targeting) technology can be applied to undruggable proteins to find new therapeutics for untreatable diseases. 💡 We're just getting started. Stay tuned for more updates, and follow us while we #foldthefuture. #BiotechInnovation #ProteinFolding #DrugDiscovery #Sibylla --- 🔗 Learn more at www.sibyllabiotech.it ---

Target identification is a fundamental first step in #drugdiscovery involving the discovery and validation of disease-associated molecular mechanism that can be modulated by a drug. In this whitepaper we introduce Evotec’s PanOmics TargetID Framework developed by our #computationalbiology and #bioinformatics teams.

Check out what we can do #NUVISAN for your Degrader projects

Did you know? #DYK? Bioxodes is not just any biotech company – it is a Belgian pioneer in medical innovation! We are on a mission to transform cutting-edge science into life-saving treatments.   🔻 The company was founded in 2013 by prof Edmond Godfroid, from the Université libre de Bruxelles based on the discovery of a molecule derived from #tick saliva with anti-clotting  and anti-inflammatory qualities.   🔻 Our principal molecule BIOX-101 (Ir-CPI) is a first-in-class drug candidate for the prevention of #thrombosis and #neuroinflammation.   🔻 BIOX-101 is currently being evaluated in a phase 2a study for the treatment of ICH (intracerebral hemorrhage).   🔻 To date, the company has raised EUR 34 M to advance its clinical pipeline.   🔻 Bioxodes has a talented team of 11 professionals, including 7 PhD’s who are experts in their field.   Stay tuned for more exciting updates and insights from Bioxodes! Follow us to learn more about our journey in transforming science into solutions that matter. 🌐 bioxodes.com #Bioxodes #Biotech #Innovation #Healthcare #DidYouKnow #MedicalResearch #LifeSciences #Belgium #ticksaliva #stroke #voiceofstroke

In collaboration with Matthew Disney at The Herbert Wertheim UF Scripps Institute for Biomedical Innovation & Technology, we used our groundbreaking MFS technology to investigate the interaction between the protein Dicer and the pre-microRNA, pre-miR-21. 📈 Using our platform, we applied slow ramps in force, increasing over time until pre-miR-21 became linearized. 🔄 We repeated the experiment, but this time with the protein Dicer bound to pre-miR-21. 📊 Raw data showed that Dicer increases the force required to linearize the RNA strand - by about 6 pN of force. 🏋️♂️ This showed us that the RNA-binding protein Dicer stabilizes the structure of pre-miR-21. 🔬 We then tested a number of drug candidates, one of which significantly inhibited Dicer : pre-microRNA21 binding. 💡 In this way, our MFS platform can unveil the dynamics of RNA-protein interactions - and help you identify drug candidates that alter biomolecular interactions. If you could directly measure the strength of biomolecular interactions, what would you explore? #RNATherapeutics #DrugDiscovery #Biotech #Interactomics

Have you ever needed to grow 5 Billion iPSC?? Check out our latest whitepaper together with the awesome folks at PBS Biotech on using a microcarrier-based approach to culture iPSC at scale. Some exciting concepts we introduce: 👉 Enhanced Cell Production: beadMATRIX+ iPSC expansion in Vertical-Wheel Bioreactors produced a larger number of high-quality cells compared to traditional aggregate culture methods. 👉 Optimized Cultivation: The process optimization, particularly the agitation rate, created an ideal culture environment for iPSC proliferation, adaptable to various downstream processes. 👉 Scalable and Consistent: The method was successfully scaled from 0.1 L to 3 L, maintaining cell viability, pluripotency, genetic integrity, and differentiation potential, supporting the development of iPSC-derived therapies.

They are so simple to use. They live longer. BS. - - - The number 1️⃣ reason why cell lines are still a thing, it's because they are cheap. The number 2️⃣ reason is that they are reproducible (at low passages). The number 3️⃣ reason is that they are published. By everyone. I can't blame people for using cell lines. There is hardly an alternative. Right? But which story would you be able to tell if you could access primary tumor material, associated normal adjacent tissue and matched materials (PBMCs, lymphnodes etc) ? Think about it for a moment. The whole story, from beginning to end. Now write it down. If you want to know how to make this a reality, write "MATCH" below to get our guide. ————————— I am Davide - Founder & CEO of Sellomics . With my life science company I bring innovative cell biology solutions to European researchers in #Academia, #Pharma, #Biotech, and #IVD. Like my content? Click my name + follow + 🔔